DZNep, an S-adenosylhomocysteine (SAH) hydrolase inhibitor, has been characterized as an EZH2 inhibitor that disrupts PRC2 and manifests antitumor activity in a variety of cancers [5, 46, 48]. Here, EZH2 is linked to cancer.